Kezar Life Sciences (KZR) reported topline results from the PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a selective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback